



June 17, 2015

Single-Cell Epigenetics Comes To The Fluidigm C1™ System

Available Free on Fluidigm's Single-Cell Community Web Portal - Script Hub™

SOUTH SAN FRANCISCO, Calif., June 17, 2015 – Fluidigm Corporation (NASDAQ:FLDM) today announced the availability of Single-Cell ATAC-seq, an epigenetics application for the C1™ system, that allows researchers to explore the regulatory systems that drive cellular function. This application is freely available to researchers on Script Hub™, a new web portal within Fluidigm's C1 Open App™ program.

As described in a paper just published in Nature entitled "[Single-cell chromatin accessibility reveals principles of regulatory variation](#)" by Jason D. Buenrostro, William J. Greenleaf, Howard Chang et.al., the researchers use ATAC-seq to identify single-cell DNA accessibility profiles from diverse cell types. Understanding the accessible regions of the genome will reveal the role of DNA-binding proteins, nucleosomes, and chromatin compaction in regulating gene expression. Until now, researchers needed at least 500 cells to identify accessible chromatin regions, which misrepresented the heterogeneity present in the biological system.

"We believe scATAC-seq will enable the interrogation of the epigenomic landscape of small or rare biological samples allowing for detailed, and potentially de novo, reconstruction of cellular differentiation or disease at the fundamental unit of investigation – the single cell," said William J. Greenleaf, Ph.D., Principal Investigator, Greenleaf Lab and Assistant Professor, Department of Genetics, Stanford University.

"We designed the C1 to be very flexible. The Open App program is an ecosystem between method development laboratories and our cell biology users. We created this program to give our users maximum flexibility to expand their capability and experimental strategy over time and to showcase creativity. We're thrilled to see the C1 community come together and pioneer the next frontier of single-cell biology: single-cell epigenetics," said Candia L. Brown, Fluidigm Single-Cell Genomics Business Director of Product Marketing.

Co-developed by the Greenleaf Lab, the Chang Lab and Fluidigm, ATAC-seq is now available on Script Hub for use with the C1 Open App IFC. The C1 Open App program is comprised of Script Hub, C1 Script Builder™, the Open App IFC, and the Open App Reagent Kit. These tools give researchers the ability to create and share the latest single-cell applications with other C1 users.

Single-Cell ATAC-seq is the first method to be published and shared on Script Hub. Other user-developed applications available on Script Hub include:

- Single-Cell CEL-seq: developed by Itai Yanai, Israel Institute of Technology
- Single-Cell STRT-seq: developed by Sten Linnarson, Karolinska Institute
- LPS Stimulation: developed by the Regev Lab, Broad Institute, and Fluidigm

Apps on Script Hub are freely available to the C1 community and are compatible with any C1 system. Each application includes the script, protocol, reference data and links to publications. All registered Script Hub users can rate and comment on published applications.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Fluidigm's new product/application, and Fluidigm's plans, objectives, expectations and/or strategies relating to such new product/application. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing and launching new products and applications; Fluidigm's sales and marketing capabilities; acceptance of new products and applications by the market and scientific community; unanticipated costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm's business and operating results are contained in Fluidigm's Quarterly Report on Form 10-Q for the three months ended March 31, 2015 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking

statements except as may be required by law.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account ([@Fluidigm](https://twitter.com/Fluidigm)), Facebook page (<https://www.facebook.com/Fluidigm>), and LinkedIn page (<https://www.linkedin.com/company/fluidigm-corporation>) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm, the Fluidigm logo, C1, Script Hub, Script Builder and Open App are trademarks or registered trademarks of Fluidigm Corporation.

Contact

Michaeline Bunting
Senior Director, Marketing
Fluidigm Corporation
650 737 4190
michaeline.bunting@fluidigm.com